Uniqure NV
Biotechnology
Uniqure NV (QURE) Stock News
The latest QURE headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.
- GlobeNewswire Inc.·
QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.
uniQure N.V. experienced a significant stock decline of over 35% on September 29, 2026, following the release of updated 48-month data for AMT-130, its investigational gene therapy for Huntington's disease. The disappointing results have prompted a securities investigation by Kehoe Law Firm on behalf of affected investors.